EUVIMEDEUVIMED entdecken
Crossref

Inhibitory effects of 190 compounds against SARS‐CoV‐2 M pr o protein: Molecular docking interactions

Gabriella B Souza, Larissa Sens, Stefan J Hammerschmidt, Natália F de Sousa iD, Maryelle A G de Carvalho, Carlos V D Dos Santos, Tiago Tizziani, Monalisa A Moreira, Luiz A E Pollo, Erlon F Martin, José S S Neto, Maique W Biavatti und 9 weitere

Archiv der Pharmazie · 2023

DOI: 10.1002/ardp.202300207 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Archiv der Pharmazie, 2023. Verfasst von Gabriella B Souza und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, CFM, Universidade Federal de Santa Catarina, Campus Universitário-Trindade, Florianópolis, Santa Catarina, Brazil. Hauptthemen laut MEDLINE: SARS-CoV-2, COVID-19. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 80 Literaturangaben. Gefördert von: Coordenação de Aperfeiçoamento de Pessoal de Nível Superior, Conselho Nacional de Desenvolvimento Científico e Tecnológico.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

COVID‐19 has caused many deaths since the first outbreak in 2019. The burden on healthcare systems around the world has been reduced by the success of vaccines. However, population adherence and the occurrence of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) variants are still challenging tasks to be affronted. In addition, the newly approved drug presents some limitations in terms of side effects and drug interference, highlighting the importance of searching for new antiviral agents against SARS‐CoV‐2. The SARS‐CoV‐2 main protease (M pr o ) represents a versatile target to search for new drug candidates due to its essential role in proteolytic activities responsible for the virus replication. In this work, a series of 190 compounds, composed of 27 natural ones and 163 synthetic compounds, were screened in vitro for their inhibitory effects against SARS‐CoV‐2 M pro . Twenty‐five compounds inhibited M pro with inhibitory constant values ( K i ) between 23.2 and 241 µM. Among them, a thiosemicarbazone derivative was the most active compound. Molecular docking studies using Protein Data Bank ID 5RG1, 5RG2, and 5RG3 crystal structures of M pro revealed important interactions identified as hydrophobic, hydrogen bonding and steric interactions with amino acid residues in the active site cavity. Overall, our findings indicate the described thiosemicarbazones as good candidates to be further explored to develop antiviral leads against SARS‐CoV‐2. Moreover, the studies showed the importance of careful evaluation of test results to detect and exclude false‐positive findings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SARS-CoV-2COVID-19HumansMolecular Docking SimulationProtease InhibitorsStructure-Activity RelationshipAntiviral AgentsMolecular Dynamics Simulation

Stichwörter der Autor:innen

SARS-CoV-2 Mproenzyme assaysmolecular dockingnatural productsthiosemicarbazones

Substanzen

Protease InhibitorsAntiviral Agents

Autor:innen und Institutionen

  • Department of Chemistry, CFM, Universidade Federal de Santa Catarina, Campus Universitário-Trindade, Florianópolis, Santa Catarina, Brazil.
  • Institute of Pharmaceutical and Biomedical Sciences, Johannes Gutenberg-University of Mainz, Mainz, Germany.
  • Chemistry Department, Exact and Nature Sciences Center, Federal University of Paraiba, Campus I, João Pessoa, Paraíba, Brazil.
  • Department of Pharmaceutical Sciences, CCS, Universidade Federal de Santa Catarina, Florianópolis, Santa Catarina, Brazil.
  • Department of Organic Chemistry, Faculty of Science University of Yaoundé 1, Yaoundé, Cameroon.
  • Department of Chemistry, University of Dschang, Dschang, Cameroon.

ORCID-Profile: Natália F de Sousa, Francisco F de Assis

Förderung

  • Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
  • Conselho Nacional de Desenvolvimento Científico e Tecnológico

Zitieren

APA

Souza, G. B., Sens, L., Hammerschmidt, S. J., de Sousa, N. F., de Carvalho, M. A. G., Dos Santos, C. V. D., Tizziani, T., Moreira, M. A., Pollo, L. A. E., Martin, E. F., Neto, J. S. S., Biavatti, M. W., de Assis, F. F., Ngadjui, B. T., Simo, I. K., Ambassa, P., Scotti, M. T., Scotti, L., Braga, A. L., …, & Sandjo, L. P. (2023). Inhibitory effects of 190 compounds against SARS‐CoV‐2 M pr o protein: Molecular docking interactions. Archiv der Pharmazie. https://doi.org/10.1002/ardp.202300207

Vancouver

Souza GB, Sens L, Hammerschmidt SJ, de Sousa NF, de Carvalho MAG, Dos Santos CVD, et al. Inhibitory effects of 190 compounds against SARS‐CoV‐2 M pr o protein: Molecular docking interactions. Archiv der Pharmazie. 2023. doi:10.1002/ardp.202300207

BibTeX
@article{Souza2023,
  author = {Souza, Gabriella B and Sens, Larissa and Hammerschmidt, Stefan J and de Sousa, Natália F and de Carvalho, Maryelle A G and Dos Santos, Carlos V D and Tizziani, Tiago and Moreira, Monalisa A and Pollo, Luiz A E and Martin, Erlon F and Neto, José S S and Biavatti, Maique W and de Assis, Francisco F and Ngadjui, Bonaventure T and Simo, Ingrid K and Ambassa, Pantaléon and Scotti, Marcus T and Scotti, Luciana and Braga, Antonio L and Schirmeister, Tanja and Sandjo, Louis P},
  title = {Inhibitory effects of 190 compounds against SARS‐CoV‐2 M pr o protein: Molecular docking interactions},
  journal = {Archiv der Pharmazie},
  year = {2023},
  doi = {10.1002/ardp.202300207}
}
Kostenlos starten →